389 related articles for article (PubMed ID: 19574786)
1. Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions.
Kang WD; Kim CH; Cho MK; Kim JW; Kim YH; Choi HS; Kim SM
Int J Gynecol Cancer; 2009 Jul; 19(5):924-8. PubMed ID: 19574786
[TBL] [Abstract][Full Text] [Related]
2. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
[TBL] [Abstract][Full Text] [Related]
3. Is human papillomavirus genotype important in predicting disease progression in women with biopsy-proven negative or CIN1 of atypical squamous cell of undetermined significance (ASC-US) cytology?
Kang WD; Ju UC; Kim SM
Gynecol Oncol; 2018 Feb; 148(2):305-310. PubMed ID: 29183629
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].
Li RZ; Shi JF; Zhou QZ; Wu RF; Li N; Wu LN; Zhou YQ; Wang Q; Liu ZH; Liu B; Qiao YL
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(5):307-11. PubMed ID: 16677522
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus genotyping as a reliable prognostic marker of recurrence after loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia (CIN2-3) especially in postmenopausal women.
Kang WD; Kim SM
Menopause; 2016 Jan; 23(1):81-6. PubMed ID: 26057824
[TBL] [Abstract][Full Text] [Related]
6. Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts.
Syrjänen K; Shabalova I; Naud P; Kozachenko V; Derchain S; Zakharchenko S; Roteli-Martins C; Nerovjna R; Longatto-Filho A; Kljukina L; Tatti S; Branovskaja M; Hammes LS; Branca M; Grunjberga V; Erzen M; Sarian LO; Juschenko A; Costa S; Podistov J; Syrjänen S;
Int J Gynecol Cancer; 2009 Jul; 19(5):934-42. PubMed ID: 19574788
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer.
Huang TH; Lai HC; Liu HW; Lin CJ; Wang KH; Ding DC; Chu TY
Int J Gynecol Cancer; 2010 May; 20(4):513-9. PubMed ID: 20442585
[TBL] [Abstract][Full Text] [Related]
8. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
[TBL] [Abstract][Full Text] [Related]
9. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
[TBL] [Abstract][Full Text] [Related]
10. Anyplex II HPV test in detection and follow-up after surgical treatment of CIN2+ lesions.
Bottari F; Iacobone AD; Radice D; Preti EP; Preti M; Franchi D; Piana AF; Sandri MT; Passerini R
J Med Virol; 2021 Nov; 93(11):6340-6346. PubMed ID: 33565607
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of human papillomavirus genotype by linear array assay in Japanese women with uterine cervical lesions and type 16 physical status by in situ hybridization.
Futai M; Watanabe J; Jobo T; Tsunoda S; Nishimura Y; Watanabe K; Okayasu I; Unno N
Int J Gynecol Cancer; 2009 Nov; 19(8):1396-401. PubMed ID: 20009896
[TBL] [Abstract][Full Text] [Related]
12. The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia.
Crosbie EJ; Bailey A; Sargent A; Gilham C; Peto J; Kitchener HC
J Clin Microbiol; 2015 Nov; 53(11):3553-9. PubMed ID: 26338859
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population.
Baasland I; Romundstad PR; Eide ML; Jonassen CM
PLoS One; 2019; 14(1):e0210997. PubMed ID: 30673759
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.
Sandri MT; Lentati P; Benini E; Dell'Orto P; Zorzino L; Carozzi FM; Maisonneuve P; Passerini R; Salvatici M; Casadio C; Boveri S; Sideri M
J Clin Microbiol; 2006 Jun; 44(6):2141-6. PubMed ID: 16757611
[TBL] [Abstract][Full Text] [Related]
16. Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.
Liao SY; Rodgers WH; Kauderer J; Bonfiglio TA; Walker JL; Darcy KM; Carter R; Hatae M; Levine L; Spirtos NM; Stanbridge EJ
Int J Cancer; 2009 Nov; 125(10):2434-40. PubMed ID: 19670419
[TBL] [Abstract][Full Text] [Related]
17. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan.
Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T
J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473
[TBL] [Abstract][Full Text] [Related]
20. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions.
Gage JC; Schiffman M; Solomon D; Wheeler CM; Castle PE
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1668-74. PubMed ID: 20615884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
